B
Bicon Pharmaceutical
Bicon Pharmaceutical manufactures and distributes pharmaceutical raw materials, patent medicines, chemicals, vaccines, and more
About Bicon Pharmaceutical
YanAn Bicon Pharmaceutical Listed Company, previously known as JiangSu Bicon Pharmaceutical Listed Company, is a China-based entity founded in 2002 and headquartered in Yan'an City. The company is publicly traded on the Shenzhen stock exchange. Its operations are diversified across three primary segments: Pharmaceuticals, New Materials, and Pharmaceutical Intermediates.
In the pharmaceuticals sector, Bicon focuses on the research, development, manufacturing, and distribution of medical products. This includes medicines for the circulatory, digestive, and respiratory systems, as well as nervous system and ophthalmic products. The company also produces modern Chinese medicines, generic drugs, bio-pharmaceuticals, and vaccines. The business distributes its products primarily within the domestic Chinese market.
The New Materials division is engaged with products such as lithium hexafluorophosphate and high-strength, high-modulus polyethylene fibers. These fibers have applications in products like anti-cut gloves, home textiles, and bulletproof helmets. The Pharmaceutical Intermediates segment manufactures key chemical components like 7-ADCA, benzaldehyde, 5.5-dimethylhydantoin, and sodium triclopyridine. Beyond these core areas, the company is also involved in freight warehousing and leasing, cultivation and sales of medicinal herbs, e-commerce, real estate development, and chemical fiber manufacturing.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 1997
- Headquarters
- Wauchula, United States
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Mar 2012 | $250M | — | Pacific Alliance Group | — |
| IPOOther financing | May 2010 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Bicon Pharmaceutical is 40 monthly website visits, down 76.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later1 investor entered at this stage
- PGPacific Alliance Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bicon Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bicon Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.